An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

BACKGROUND AND RATIONALE BORTEZOMIB: (PS-341, VELCADE®) is a selective inhibitor of the 26S proteasome, an integral component of the ubiquitinproteasome pathway. This phase II study evaluated the activity and tolerability of bortezomib in unresectable hepatocellular carcinoma (HCC) patients. METHODS...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kim, George P., Mahoney, Michelle R., Szydlo, Daniel, Mok, Tony S. K., Marshke, Robert, Holen, Kyle, Picus, Joel, Boyer, Michael, Pitot, Henry C., Rubin, Joseph, Philip, Philip A., Nowak, Anna, Wright, John J., Erlichman, Charles
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896232/
https://ncbi.nlm.nih.gov/pubmed/20839030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9532-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares